Protocol Ledger

NCT05837897 · Phase III · RECRUITING

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Interventional Phase III clinical trial protocol NCT05837897 sponsored by Takeda in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-16 Enrollment: 408 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05837897
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)408 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05837897
Protocol FieldVerified Registry Value
NCT IdentifierNCT05837897
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment408 participants (ESTIMATED)
Registered Start Date2023-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI